1. Home
  2. SLDP vs EDIT Comparison

SLDP vs EDIT Comparison

Compare SLDP & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Solid Power Inc.

SLDP

Solid Power Inc.

N/A

Current Price

$2.27

Market Cap

463.5M

Sector

Energy

ML Signal

N/A

Logo Editas Medicine Inc.

EDIT

Editas Medicine Inc.

N/A

Current Price

$2.94

Market Cap

432.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SLDP
EDIT
Founded
2011
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Electrical Products
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
463.5M
432.8M
IPO Year
2021
2016

Fundamental Metrics

Financial Performance
Metric
SLDP
EDIT
Price
$2.27
$2.94
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
5
Target Price
$7.00
$5.30
AVG Volume (30 Days)
3.5M
1.9M
Earning Date
05-05-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
5.56
37.50
EPS
N/A
N/A
Revenue
$21,747,000.00
$31,937,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$48.90
N/A
P/E Ratio
N/A
N/A
Revenue Growth
7.98
132.64
52 Week Low
$1.98
$1.66
52 Week High
$8.86
$4.54

Technical Indicators

Market Signals
Indicator
SLDP
EDIT
Relative Strength Index (RSI) 45.78 54.20
Support Level $2.21 $2.43
Resistance Level $2.50 $3.21
Average True Range (ATR) 0.11 0.18
MACD 0.02 0.04
Stochastic Oscillator 44.19 61.69

Price Performance

Historical Comparison
SLDP
EDIT

About SLDP Solid Power Inc.

Solid Power Inc develops solid-state battery technology and manufacturing processes. Its sulfide-based solid electrolyte material replaces the liquid or gel electrolyte used in traditional lithium-ion battery cells and enables improvement in energy density, battery life and safety performance. The company produces electrolytes on two pilot manufacturing lines using a batch manufacturing process for customer sampling and internal cell development, and manufactures solid-state cells on pre-pilot and pilot cell manufacturing lines. Its cell manufacturing processes are developed around industry-standard lithium-ion battery manufacturing processes and equipment, and it manufactures all cell designs, including cathodes and anodes, using materials sourced from external suppliers.

About EDIT Editas Medicine Inc.

Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.

Share on Social Networks: